Clinical Trials
15 trialsNCT06901531 2026-06-05
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT05365581 2026-05-28
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT05968326 2026-05-11
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT05065736 2026-03-19
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06128343 2026-03-19
BACAP-2
University Hospital, Toulouse
Recruiting
NCT06902545 2026-03-11
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Astellas Pharma Inc
Recruiting
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT00349830 2026-02-10
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Stanford University
Recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT05116072 2025-09-25
TPIAT-01
University Hospital, Lille
Phase 1/2 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT07026149 2025-06-18
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2 Recruiting
NCT02973828 2025-05-06
PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy
Institute of Cancer Research, United Kingdom
Recruiting
NCT02292641 2024-10-17
Beyond TME Origins
Imperial College London
Phase NA Recruiting
NCT05101356 2024-05-21
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
University of California, Davis
Phase 1/2 Recruiting